| Test Code | D0600 | |
| Test Summary | This test provides analysis and interpretation of a single variant or known familial mutation |
|
| Turn-Around-Time (TAT)* | 3 - 5 weeks | |
| Acceptable Sample Types | Whole Blood (EDTA) DNA, Isolated Dried Blood Spots Saliva |
|
| Acceptable Billing Types |
Self (patient) Payment Institutional Billing
|
|
| NY Approved | No | |
| Self (patient) Price | $350.00 | |
| Institutional Price | $350.00 |
This test involves targeted sequencing, analysis, and interpretation of a single variant or known familial mutation by an appropriate technology (ex. Sanger sequencing).
- Known disease causing variant in the family
- Determination of inheritance of a known variant
- Family linkage studies
Only amplification of the regions of the gene in which the targeted variant is located is performed; other regions of the gene are not analyzed. The products are sequenced in the forward and reverse directions. Nucleotide numbering is based on GenBank accession number; nucleotide 1 corresponds to the A of the start codon ATG. This analysis cannot detect single and multi-exon deletions and duplications, or variants in regions not analyzed. This assay is not designed to detect mosaicism; possible cases of mosaicism may be investigated at the discretion of the laboratory director. Variants are evaluated by their frequency as reported in public databases such as the Genome Aggregation Database (gnomAD), Human Gene Mutation Database (HGMD), and ClinVar. Variants that have a frequency greater than expected given the prevalence of disease are considered to be benign. In some cases, due to the complexity of the sequence, not all variants in the flanking intronic regions are able to be analyzed. The interpretation of variants is based on our current understanding of the genes involved. This understanding may change over time as more information becomes available.
EDTA (purple top)
Infants (< 2-years): 2 to 3 mL; Children (>2-years): 3 to 5 mL; Older children and adults: Minimum 5mL. The blood tube should be inverted several times immediately after blood collection to prevent coagulation.
Clotted or hemolyzed samples are not accepted.
Required DNA Quantity by Test Type*:
- Next Generation Sequencing (NGS): Send >1000 ng total gDNA @ >15 ng/μL. Please ship samples in 10mM Tris. Do not use EDTA.
- Sanger Sequencing: Send >500 ng total gDNA @ >15 ng/μL (varies by the size of the gene and the variants requested).
- Non-Sanger Sequencing Tests: Send >500 ng total gDNA @ >15 ng/μL.
- Research Laboratories: DNA extracted in research laboratories is not acceptable. Only under exceptional circumstances (e.g., proband not available) will DNA extracted in a research laboratory be accepted for clinical testing. Additional testing (e.g., of other family members) may be required to confirm results.
- Laboratories outside the United States: Non-US laboratories are not subject to CLIA regulations and will be reviewed on a case-by-case basis. Please call to speak with a laboratory genetic counselor prior to submitting a DNA sample from any non-CLIA certified laboratory.
- Special Notes: If extracted DNA is submitted, information regarding the method used for extraction should be sent along with the sample.
Dried blood spot card
Follow kit instructions. Briefly, allow blood to saturate card until indicated areas are filled and blood has soaked through card. Air dry card at ambient temperature for at least 3 hours.
- NBS: Please contact PKIG to request the StepOne® kit.
- Gene Sequencing: Please contact PKIG to request the DBS collection kit.
- For pre-punched DBS: The required minimum 6 punches with 3.2 mm or 4 punches 4.75 mm.
Oragene™ Saliva Collection Kit or ORAcollect-Dx kit
Collect saliva on an Oragene™ Saliva Collection Kit ORAcollect-Dx kit according to the manufacturer’s instructions.
Please contact PerkinElmer to request the saliva collection kit for patients that cannot provide a blood sample as whole blood is the preferred sample.